Campbell W B, Graham R M, Jackson E K
J Clin Invest. 1979 Aug;64(2):448-56. doi: 10.1172/JCI109482.
Renal prostaglandins (PG) appear to mediate renin release due to stimulation of the intrarenal baroreceptor, but not that due to activation of the macula densa. However, as the role of PG in sympathetically mediated renin release remains unclear, a possible interrelationship between these factors was examined in conscious rats. Hydralazine increased the serum renin levels from 3.1+/-0.8 to 16.7+/-3.0 ng/ml per h at a dose of 1 mg/kg. Indomethacin (5 mg/kg) suppressed urinary PGE(2) and PGF(2alpha) excretion by 89 and 74%, respectively, arachidonate hypotension by 82%, and inhibited the elevated renin levels from hydralazine by 100% without altering the hypotensive effect of the drug. Another PG synthetase inhibitor, meclofenamate, was also effective in attenuating hydralazine-induced renin release, urinary PGE(2) and PGF(2alpha) excretion, and arachidonate hypotension. Isoproterenol, a nonselective beta-adrenergic agonist, increased heart rate, lowered blood pressure, and also stimulated the release of renin when administered intraperitoneally. However, intrarenal infusion of the drug only resulted in increased renin release. Indomethacin inhibited isoproterenol-induced renin release by 66 and 67%, respectively, without altering the hemodynamic effects associated with the intraperitoneal administration of the drug. The selective beta(1) agonist, H133/22, increased the release of renin and heart rate in a dose-related manner without altering blood pressure. H133/22-induced renin release was inhibited by 80% by indomethacin pretreatment. Finally, intrarenal infusions of dibutyryl cyclic AMP (3 mg/kg per min) increased the serum activity from 4.1+/-0.2 to 20.4+/-3.9 ng/ml per h without altering mean arterial pressure. Indomethacin inhibited this renin response to dibutyryl cyclic AMP by 96%. Thus, renal PG appear to be important mediators of sympathetically stimulated renin release acting as a site distal to the beta-adrenergic receptor.
肾前列腺素(PG)似乎通过刺激肾内压力感受器介导肾素释放,但不是通过致密斑激活介导的肾素释放。然而,由于PG在交感神经介导的肾素释放中的作用仍不清楚,因此在清醒大鼠中研究了这些因素之间可能的相互关系。肼屈嗪以1mg/kg的剂量使血清肾素水平从每小时3.1±0.8 ng/ml增加到16.7±3.0 ng/ml。吲哚美辛(5mg/kg)分别使尿PGE₂和PGF₂α排泄量减少89%和74%,使花生四烯酸诱导的低血压降低82%,并完全抑制肼屈嗪引起的肾素水平升高,而不改变该药物的降压作用。另一种PG合成酶抑制剂甲氯芬那酸也能有效减弱肼屈嗪诱导的肾素释放、尿PGE₂和PGF₂α排泄以及花生四烯酸诱导的低血压。异丙肾上腺素,一种非选择性β-肾上腺素能激动剂,腹腔注射时可增加心率、降低血压,并刺激肾素释放。然而,肾内输注该药物仅导致肾素释放增加。吲哚美辛分别抑制异丙肾上腺素诱导的肾素释放66%和67%,而不改变与腹腔注射该药物相关的血流动力学效应。选择性β₁激动剂H133/22以剂量相关的方式增加肾素释放和心率,而不改变血压。吲哚美辛预处理可使H133/22诱导的肾素释放减少80%。最后,肾内输注二丁酰环磷腺苷(每分钟3mg/kg)使血清肾素活性从每小时4.1±0.2 ng/ml增加到20.4±3.9 ng/ml,而不改变平均动脉压。吲哚美辛抑制二丁酰环磷腺苷引起的肾素反应达96%。因此,肾PG似乎是交感神经刺激肾素释放的重要介质,作用于β-肾上腺素能受体的远端位点。